Comorbidities

Discover our last Discover and news about the comorbidities of NASH / NAFLD via educational video content obtained from key opinion leaders.

Prof. Zelber-Sagi

Lifestyle prevention & treatment for NAFLD

Currently, there are no Food and Drug Administration (FDA)-approved or European Medicines Agency (EMA)-approved therapies for NASH and only lifestyles interventions are recommended for the treatment of NAFLD. Prof Zelber-Sagi (Haifa, Israel) reviews best practices for lifestyle interventions in patients with NAFLD. She warns us against ultra-processed foods and drinks, that are so common in the Western world. She also highlights the benefits of the Mediterranean diet and physical activity.
View More ⏩Lifestyle prevention & treatment for NAFLD
Prof. Jeffrey V Lazarus

Defining comprehensive models of care for NAFLD Liver health specialists

NAFLD places a substantial burden on healthcare systems and receives little attention from public health authorities. Ambitious measures are needed to improve preparedness globally. Prof Lazarus, Spain, discusses how to establish care pathways tailored to meet patients needs but also that optimally use existing resources. Modifiable risks factors are particularly important in a comprehensive strategy.
View More ⏩Defining comprehensive models of care for NAFLD Liver health specialists
Prof. Sven Francque

From number-one liver disease to multi-system disease: NASH, a major unmet clinical need

In this opening talk of the 1st PanNASH webinar, Prof. Sven Francque (Belgium), one of the PanNASH editors, explains how NASH, the number-one liver disease, is part of a multisystem disease. He also sheds light on the etiology of this disease, its epidemiology, symptoms and consequences.
View More ⏩From number-one liver disease to multi-system disease: NASH, a major unmet clinical need
Dr. Byrne

Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2

It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.
View More ⏩Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2
Prof. Kenneth Cusi

Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D

Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
View More ⏩Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D
Prof. F. Tacke

The multiple risks in NAFLD by Prof. F. Tacke

In NAFLD, the liver is both victim and motor of a multisystem disease. Liver disease is not limited to the liver itself but has an impact on glycemic control in the body. Prof. Tacke discusses this vicious cycle and how NAFLD may add to coexisting risk factors and is predictor of morbidity and mortality. He shows why this is also important to develop new treatment strategies.
View More ⏩The multiple risks in NAFLD by Prof. F. Tacke

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES